| Cortexyme is a clinical stage biopharmaceutical company focused on developing therapeutics based on data supporting a new theory of the cause of Alzheimer's disease and other degenerative disorders. Co. is targeting a specific, infectious pathogen tied to neurodegeneration and chronic inflammation in humans and animal models. Co.'s proprietary main drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor. We show 6 historical shares outstanding datapoints in our CRTX shares outstanding history coverage, used to compute CRTX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CRTX market cap history over the course of time is important for investors
interested in comparing CRTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CRTX versus a peer is one thing; comparing
CRTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CRTX can fluctuate over the course of history.
With this page we aim to empower investors researching CRTX by allowing them to research the CRTX market cap history.